4Bio Capital: Appointment of Professor Akiko Iwasaki to Scientific Advisory Board Professor of Molecular, Cellular and Developmental Biology and Immunology at Yale University Principal investigator at the Howard Hughes Medical Institute Brings extensive experience in Immunology within the field of infectious diseases, most recently in COVID-19 18 December 2020 LONDON & BOSTON - 4BIO Capital ("4BIO" or "the Group"), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Akiko Iwasaki to its Scientific Advisory Board (SAB). Professor Iwasaki has made significant contributions towards understanding innate and adaptive immunity. Throughout her research career she has made major breakthroughs including the demonstration of tissue-specific properties of dendritic cells, how DNA vaccines elicit an immune response, and being the first group to create a mouse model of vaginal Zika infection. She has received a number of honours in her career including the Inspiring yale awards in 2017 and 2020, and being elected to the National Academy of Sciences in 2018 and to the National Academy of Medicine in 2019. Her publications in prestigious journals have been widely cited, and she is also well known as an advocate for women in science.